Hiv-associated Lipodystrophy

• FDA approval · 2025-03-25
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc.

• FDA approval · 2024-02-27
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc. This action updates the product's regulator…

• FDA approval · 2019-07-05
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc., indicating an additional FDA actio…

• FDA approval · 2019-01-18
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc., indicating an update or addition to it…

• FDA approval · 2015-06-08
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  FDA approves a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2015-02-09
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc. This action pertains to the sup…

• FDA approval · 2014-12-15
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies, related to HIV-associated lipodystrophy.

• FDA approval · 2013-01-07
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc.

• FDA approval · 2011-11-29
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies.

• FDA approval · 2010-11-10
  FDA Approved: EGRIFTA WR — Original Application (Theratechnologies Inc.)

  FDA approved EGRIFTA WR (tesamorelin) from Theratechnologies Inc. through an original application. It is indicated for HIV-associated lipody…

• FDA approval ·
  FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

  The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc.